A Phase I-II Randomized Autologous Bone Marrow Derived Aldehyde Dehydrogenase-Bright (ALDHbr) Cells Against Unfractionated Autologous Mononuclear Bone Marrow in Patients With Rutherford 4 or 5 Peripheral Arterial Occlusive Disease
Latest Information Update: 12 May 2014
At a glance
- Drugs ALD 301 (Primary)
- Indications Peripheral arterial occlusive disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Aldagen
Most Recent Events
- 12 May 2014 New trial record